Literature DB >> 7847866

Topical lidocaine gel relieves postherpetic neuralgia.

M C Rowbotham1, P S Davies, H L Fields.   

Abstract

Postherpetic neuralgia (PHN) following herpes zoster is a common and disabling neuropathic pain syndrome. In a double-blind, three-session study, 5% lidocaine gel or vehicle was applied simultaneously to both the area of pain and to the contralateral mirror-image unaffected skin. In the local session, lidocaine gel was applied to the painful skin area. In the remote session, lidocaine gel was applied to mirror-image skin. In the placebo session, vehicle was applied bilaterally. For cranial PHN, gel was applied without occlusion for 8 hours. For limb or torso PHN, gel was applied under occlusion for 24 hours. The 16 subjects with cranial PHN reported pain relief significantly favoring local drug application at 30 minutes, 2, 4, and 8 hours. The 23 subjects with torso or limb PHN reported significantly lower pain intensity with local drug application at 8 hours and both pain relief and reduced pain intensity at 24 hours. Remote lidocaine application to mirror-image skin was no different from placebo. No systemic adverse effects were reported and blood levels did not exceed 0.6 microgram/ml. Topical application of 5% lidocaine gel relieves PHN pain by a direct drug action on painful skin.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7847866     DOI: 10.1002/ana.410370216

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  44 in total

Review 1.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

Review 2.  The pharmacotherapy of chronic pain: a review.

Authors:  Mary E Lynch; C Peter N Watson
Journal:  Pain Res Manag       Date:  2006       Impact factor: 3.037

Review 3.  WITHDRAWN: Topical lidocaine for the treatment of postherpetic neuralgia.

Authors:  Waqas Khaliq; Serena Alam; Naveen Kumar Puri
Journal:  Cochrane Database Syst Rev       Date:  2013-10-28

Review 4.  Reappraising neuropathic pain in humans--how symptoms help disclose mechanisms.

Authors:  Andrea Truini; Luis Garcia-Larrea; Giorgio Cruccu
Journal:  Nat Rev Neurol       Date:  2013-09-10       Impact factor: 42.937

Review 5.  Optimal treatment of phantom limb pain in the elderly.

Authors:  R Baron; G Wasner; V Lindner
Journal:  Drugs Aging       Date:  1998-05       Impact factor: 3.923

6.  Lidocaine patch 5%.

Authors:  A M Comer; H M Lamb
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

7.  Pharmacological management of chronic neuropathic pain - consensus statement and guidelines from the Canadian Pain Society.

Authors:  D E Moulin; A J Clark; I Gilron; M A Ware; C P N Watson; B J Sessle; T Coderre; P K Morley-Forster; J Stinson; A Boulanger; P Peng; G A Finley; P Taenzer; P Squire; D Dion; A Cholkan; A Gilani; A Gordon; J Henry; R Jovey; M Lynch; A Mailis-Gagnon; A Panju; G B Rollman; A Velly
Journal:  Pain Res Manag       Date:  2007       Impact factor: 3.037

8.  Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.

Authors:  Hiltrud Liedgens; Nadine Hertel; Anja Gabriel; Mark Nuijten; Helen Dakin; Stephen Mitchell; Barbara Poulsen Nautrup
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

Review 9.  An evidence-based algorithm for the treatment of neuropathic pain.

Authors:  Nanna B Finnerup; Marit Otto; Troels S Jensen; Søren H Sindrup
Journal:  MedGenMed       Date:  2007-05-15

Review 10.  Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia.

Authors:  Pamela S Davies; Bradley S Galer
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.